NA LI to Tachycardia, Ventricular
This is a "connection" page, showing publications NA LI has written about Tachycardia, Ventricular.
Connection Strength
1.088
-
Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. Int J Cardiol. 2017 Jan 15; 227:668-673.
Score: 0.467
-
Cardiac crises: Cardiac arrhythmias and cardiomyopathy during TANGO2 deficiency related metabolic crises. Heart Rhythm. 2022 10; 19(10):1673-1681.
Score: 0.171
-
In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Res. 2018 Sep 28; 123(8):953-963.
Score: 0.133
-
EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2. Heart Rhythm. 2018 04; 15(4):578-586.
Score: 0.126
-
Inhibition of CaMKII phosphorylation of RyR2 prevents inducible ventricular arrhythmias in mice with Duchenne muscular dystrophy. Heart Rhythm. 2013 Apr; 10(4):592-9.
Score: 0.089
-
Sudden infant death syndrome in mice with an inherited mutation in RyR2. Circ Arrhythm Electrophysiol. 2009 Dec; 2(6):677-85.
Score: 0.072
-
CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. J Mol Cell Cardiol. 2016 09; 98:62-72.
Score: 0.028